Author

U. M. Moll

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1

Frequent Co-Authors

J. Li· 2 shared R. Schulz-Heddergott· 2 shared T. Isermann· 2 shared A. Nemajerova· 1 shared A. P. Delgado· 1 shared A. Stender· 1 shared B. J. Nelson· 1 shared B. Mundt· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Li

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition

T. Isermann, K. L. Schneider, F. Wegwitz, T. De Oliveira, L.-C. Conradi, V. Volk, F. Feuerhake, B. Papke, S. Stintzing, B. Mundt, F. Kuehnel, U. M. Moll, R. Schulz-Heddergott

This study shows that combining HSP90 inhibitors with p53 activation or CDK4/6 inhibition enhances colorectal cancer therapy by disrupting the HSF1-HSR feedback loop.

bioRxiv · Feb 22, 2024Cancer Biology

Single-cell transcriptome analysis reveals evolutionarily conserved features during the transition from normal breast stromal cells to cancer-associated fibroblasts

A. P. Delgado, A. Nemajerova, B. J. Nelson, M. Rao, J. Li, N. Marchenko, J. Preall, U. M. Moll, M. Egeblad, S. Powers

This study identifies conserved CAF subtypes in human and mouse breast tissues and reveals shared molecular mechanisms in their transition from normal stromal cells.

bioRxiv · May 5, 2022 · PreprintCancer Biology

Suppression of HSF1 activity by wildtype p53 creates the driving force for p53 loss-of-heterozygosity, enabling mutant p53 stabilization and invasion

O. C. Sener, A. Stender, L. Klemke, N. Stark, T. Isermann, J. Li, U. M. Moll, R. Schulz-Heddergott

This paper identifies the WTp53-HSF1 axis as the driver of p53LOH in colorectal tumors, enabling mutp53 stabilization and invasion.

bioRxiv · Apr 23, 2020Cancer Biology